Sun Builds On Psoriasis Data But Can It Hold In Crowded Space?

Sun Pharma’s executive vice president, biologics and dermatology, Jesper Ostergaard Jensen, elaborates on some aspects of the recent encouraging data around the company’s late stage psoriasis asset, tildrakizumab. Jensen also tells Scrip that the firm is upbeat about its acne and photodynamic therapy products in the US.

Marathon runners
Sun Pharma's tildrakizumab faces a crowded competitive space • Source: Shutterstock

Sun Pharmaceutical Industries Ltd. has underscored the potential long-term efficacy of its late stage psoriasis asset, tildrakizumab, as part of recent new analyses from the Phase I and the pivotal Phase III clinical trials (reSURFACE 1 and 2) of the investigational IL-23p19 inhibitor.

The pivotal Phase III reSURFACE trial results presented to date are through week 64 and indicate “significantly improved” skin clearance...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

2025’s Biggest Launches – Half-Year Progress Report

 

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

More from R&D

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Dizal’s Zegfrovy Wins US NSCLC Approval, At Lower Dose Than In China

 

Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.